Figure 2 - uploaded by Angela Rosenbohm
Content may be subject to copyright.
Age standardized incidence ratios of ALS registry data at county level. Abbreviation and explanation: significant counties (light green: ‘Confidence Interval’ CI below the cut-off value of 1 means less observed cases as expected; dark red: CI above the cut-off value means more observed cases as expected), not significant counties are displayed in dark-green and light red. doi:10.1371/journal.pone.0093932.g002 

Age standardized incidence ratios of ALS registry data at county level. Abbreviation and explanation: significant counties (light green: ‘Confidence Interval’ CI below the cut-off value of 1 means less observed cases as expected; dark red: CI above the cut-off value means more observed cases as expected), not significant counties are displayed in dark-green and light red. doi:10.1371/journal.pone.0093932.g002 

Source publication
Article
Full-text available
Objective of this paper was to investigate the incidence, potential geographical clusters and the completeness of the amyotrophic lateral sclerosis (ALS) registry in Southern Germany (Swabia). Age-standardized incidence rates (ASR) and ratios (SIR) as well as 95% confidence intervals (CI) were estimated at county level. Capture-recapture (CARE) pro...

Contexts in source publication

Context 1
... or absent are shown in Fig. 3 . The percentage of log-linear estimated missing ALS cases in the target population was estimated to be 18.9%. Correspondingly, a maximum total of 540 (SD = 13.1) ALS cases is estimated where source dependency is taken into account and estimation bias were minimized in optimizing logistical approaches. Compared to other statistical CARE procedures, the log-linear model included all available intersections of the data sources and took the dependency between the data sources into account. Alternative methods, which are considered less accurate, yielded results from 15.8% to 35.7% depending on the chosen estimation method and the data sources included ( table 1 ). In our study, the alternative CARE methods turned out to be conservative in source dependency in relation to sparse data and the corresponding results seemed strongly biased depending on the selection of intersections terms. Information of included interaction terms are set out in table 1 . A comparison of the total estimated ALS cases in the target population ( N ^ = 520–681) is summarized in table 1 by the missing percentages regarding the observed total ALS cases ( N = 438). Adding the estimated 18.9% CARE missing cases to the observed ALS cases, the ASR increased to 3.1 per 100,000 PY as expected for case ascertainment in the ALS registry before study beginning. Based on log-linear CARE estimated total ALS cases in the study region, the number of ALS cases, demographic characteristics and the completeness in percentage in the respective data sources are given in the following table 2 . Based on the first population based ALS registry in Germany covering a geographically defined region with about 8.4 million inhabitants, a crude incidence rate of ALS of 2.6 per 100,000 PY was estimated. The exact European ASR was 2.5 per 100,000 PY (95%-CI: 2.3 to 2.7). The male/female ratio was 1.1 and the age- distribution of the ALS cases peaked in the age group 70–74 years. The observed incidence rates and the peak were consistent with findings from other European countries, indicating that the ALS registry Swabia is well implemented. Although we found some geographical incidence variation, the differences were not statistically significant and most likely represent chance variation. The estimated completeness was 81.1% and indicates a good coverage of the registry. After correction for potentially missing cases, the ASR was estimated to a maximum of 3.1 per 100,000 PY. In our study, the crude annual incidence rate for 2009/2010 was comparable to the estimated average crude incidence rate of ALS in Europe. The ASR in Swabia was in line with the different ASRs ranging in European countries from a low of 1.5 in Lancashire and a high of 2.7 in Ireland per 100,000 PY [3,35]. A peak incidence in the age group 70–74 years is also reported by other authors [3,7,8]. A decreasing trend in the gender ratio towards one as described in recent studies [9,10] was clearly evident from our data. Our study results were also in line with ALS-incidence rates in Canada, which range from 1.6 to 2.4 for crude incidences and 2.1 to 2.3 for ASRs [36]. Higher ASRs were observed in previous studies (USA standard population) for the age group of 45 to 74 years in studies from Canada, Denmark, Finland, Italy, Ireland, Israel, Sardinia, Scotland, Sweden, USA, with a ASR range of 2.1 (Israel) to 8.5 (Middle Finland) [8]. These differences can be explained e.g. by to possible geographical variation, the underlying population size, the completeness of the registries or bias produced by weights of the standard population. Wide 95% CIs of ASRs could also partly explain the variation in the ASRs, possibly revealing different methods used in the registries to estimate epidemiological parameters. Analyzing ALS data, the geographical variation of incidences might be a result of the standard deviation or standard error occurring from the issue of sparse data. In 1996, Pringle mentioned that a compromise could be summarizing two extremes, small scaled cartographical presentation of the estimated risks (focus attention on smaller areas) and probability maps (focus attention on larger areas). Empirical Bayesian approaches offer such a possible solution by providing estimates of relative risks e.g. for each county and converting them into rates by simply multiplying them by the overall rate [37]. Future studies that compare Bayesian corrected epidemiological measures at county level with the measures estimated in this work, should be considered since enhanced ALS data are provided and maybe added for underreported counties. To reduce bias, additional estimates for the new, old and exact European standard population were calculated in our study with an ASR of 2.0, 1.9 and 2.5 respectively. Based on the SIRs ascertained with the suggested European rates in [3], more ALS cases were expected in some counties suggesting underreporting in these counties (light green colored; Fig. 2 ). Possible explanations for rates lower than expected might be that patients corresponding to the region visited clinics in neighboring counties. However, all clinics in the study region as well as clinics in neighboring counties outside the study region were contacted at regular intervals (3 to 6 months) to reduce delayed notifications and to improve the data acquisition. Counties with high SIR are suggestive for disease clusters and could be related to familiar cases. However, the familial cases were not observed in the two counties with high SIR in our study. Thus, possible other risk factors or as yet unidentified familial cases should be explored in future studies. The completeness of the registry might also be influenced by unknown or delayed diagnosis. Generally, previous studies reported a median of about 9–13 months diagnostic delay from symptom onset and a possible underreporting in some geographic areas [3,38–40]. The estimated percentage of CARE missing ALS cases in our study (range of 15.8% to 35.7%) has to be compared with other ALS registries from a low of 2.2% in Scotland [41] or Uruguay of 3.5% [14] and a high of 31.2% in Texas (Harris County) [28] or in France (Limousin) of 34.7% [17]. Consistent with our findings, a study from the Netherlands [7] reported with 19.6% CARE missing ALS cases and a CARE estimated incidence rate of 2.8 in a study population of 16.5 Mio inhabitants. However, differences could be explained by the different regions with different conditions or due to different methods used. Differences in the number of data sources included, the interaction terms the study period chosen or the data source dependency considered in a model, were all discussed as potential sources of bias [7,16,17,28,42]. In terms of the estimation of the registry completeness, several statistical procedures with CARE methods were compared to consider the sparse data in each data source and to reduce estimation bias caused by methodological approaches ( Methods S1 ). Although the models (especially Poisson distribution related) seem to be robust concerning sparse data, results show large variation as soon as more data sources are excluded from the model. A robust model for example was presented by Schnabel in Chapman et al. [32], with the advantage of each intersection of the data sources being approximately Poisson distributed [32]. However, main limitations with CARE methods are the limited accuracy of estimate due to uncertainties in source dependencies. The application of these methods was complex to evaluate the completeness of the registry. The case ascertainment was evaluated partly in some of these methods strongly biased regarding the intersection terms in our study as well as CARE estimates with only 2 data sources due to the source dependencies. Similar observations were made in the ALS study of Wittie et al. [16,17,28]. We therefore compared log-linear approaches to take the source dependency into account, where each ALS cases had to be modeled as ‘present’ or ‘absent’ in a data source and provided in a separate dataset for the log linear model calculations as suggested by Chao et al. [33]. This method seemed to be the most adequate method in estimating the case ascertainment of rare diseases, because the dependency between multiple data sources of sparse data are included as separate log functions into the main model [33]. In general, our results were comparable to data on epidemiological characteristics collected in the EURALS project [43,44], which facilitated the data quality evaluation. Data quality assurance and plausibility-check procedures have been implemented ensuring high standards of our data collection and management procedures. Newly diagnosed ALS cases were reviewed by experienced neurologists according to the revised EL Escorial criteria [20–22] to assure high international standards. To maintain a high completeness of the registry, constant professional training of study staff and collaborators and the availability of study nurses to recover all ALS cases all over the study region as was provided. Due to the diagnosis delay, data on retrospective patients were still recorded long after the end of the recruitment period in the retrospective arm of the study. Another limitation was the lack of access to an independent mortality data source on an individual level, due to German administrative regulations. The high coverage of the CARE estimated completeness of the successfully implemented ALS registry Swabia indicates excellent quality for future projects. Interesting research aspects will cover a cluster analysis at zip code level by means of spatial scan statistics including potential, environmental risk factors in ALS cases at zip code level. Following cooperating partners provided data for the ALS registry ...
Context 2
... and analysis center is located at the Institute of Epidemiology and Medical Biometry of Ulm University. Here only pseudonymized data of the cases are stored and internal quality checks and analyses are performed on a routine basis. Epidemiological measures and county levels. We calculated the age-standardized rates (ASR) for the target population per 100,000 PY based on the exact European population of the year 2010 with a 95% confidence interval (CI). We applied the direct method in 5-year age-categories [24] over all counties combined as well as for each county in Southern Germany. To determine possible geographical clusters, we displayed small-scale estimated epidemiological measures at county-level. To compare the influence of the different population weights and achieve comparability with other published data, the ASRs were additionally calculated with the European standard population of the year 1990 and an old European standard population of the year 1976 [25]. To visualize counties in which significantly more ALS cases were observed than expected, we also determined age- standardized incidence ratios (SIR) at county-level. Expected ALS cases in each county were estimated using 5-years age class rates of combined European data from 6 ALS registries [3]. Analysis for this paper was performed using SAS software [26]. Increased rates of counties were investigated with Spatial Scan Statistics in SatScan [27]. estimation methods. For the statistical CARE procedures, we included five ALS data sources with all natural registered ALS cases in the respective ALS data source, which were according to the health care characteristics of the notifying partners: (1) ALS registry Swabia, (2) clinical centers, (3) university clinics, (4) small clinics and hospitals, (5) private neurological practice doctors and medical care centers. The information of ALS cases in the respective data source intersections (multiple records) is the main precondition in CARE methods. The simplest method is the origin variant of Petersen dual system estimator N , a simple equation of n 1 \ n 2 = n 2 ~ n 1 = N [28]. It is commonly used in the wildness to track animal populations with only 2 sources, where animals were captured and marked in a population ( n 1 ) and recaptured again ( n 2 ). We compared several statistical CARE procedures: simple Petersen estimates with simple techniques of the set theory [28], Chapman estimates [29], nearly unbiased maximum likelihood estimator modified firstly by Schnabel [29–31], Schnabel/Chapman estimates for Poisson distributions for the sparse data in rare diseases [32], and log linear model approaches to control for bias [33]. With regard to the latter, possible dependence between data sources is taken under consideration with log linear approaches to adjust among multiple sources. This method requires that data source characteristics (including intersections) of each patient are separately modeled for the main log linear model. According to the requirements of the linear model, we categorized our ALS cases by their natural occurrence in the data source intersections and applied the interactive freeware program CARE [34] in combination with Gsrun 5.0 according to the suggestions of Chao et al. [33] to ascertain possible missing cases in the ALS registry Swabia. In total, 520 suspected ALS cases were reported, of whom 8 cases could not be confirmed, and 74 ALS cases were multiple recorded. Thus, 438 confirmed ALS cases remained, of whom 53% were men and 47% women. The gender ratio (men:women) was 1.1. The age distribution of all ALS cases peaked in the age group 70–74 years. Men peaked in the age group 65–69 and women in 70–74 age group. Male patients had a mean age at diagnosis (SD) of 63.8 (11.9) years and female patients a mean age at diagnosis of 66.0 (12.2) years. Overall, the crude incidence was estimated to be 2.6 per 100,000 PY. The age-standardized exact European population (data from year 2010) incidence rate was 2.5 per 100,000 PY (95% CI: 2.3–2.7). The 95% CI based on the Poisson distribution did not differ. Depending on the selection of the European population to standardize to, the ASRs for retrospective data varied from 1.9 to 2.5 per 100,000 PY for the whole study region and differed in their geographical representation of the 40 counties. A comparison of ASRs at county level is given in Fig. 1. As displayed in Fig. 1 , using the exact EU population, the highest ASR was observed in the county Bodenseekreis with 4.4 per 100,000 PY and the lowest with 0.6 per 100,000 PY in the county Lindau. With other EU standard populations, other high incidence counties disappeared (e.g. G ̈ppingen with the old standard population of 1976). Spatial Scan statistics and hypothesis testing were therefore considered to test for geographical differences. Comparing the 40 counties in the target population, high-ratio counties (G ̈ppingen: SIR = 1.9, CI = 1.2–2.8; ‘Bodensee’: SIR = 1.8, CI = 1.1–2.8; Fig. 2 (dark-red colored)) were determined, but the difference in variation in the overall pattern was not statistically significant (p-value = 0.17 and p-value = 0.43, respectively). Due to multiple information of ALS recording, the case ascertainment of the ALS registry Swabia was estimated by 5 data sources: (1) ALS registry Swabia (N = 438); (2) University clinics (N = 256); (3) clinical centers (N = 122); (4) small clinics and hospitals (N = 130) and (5) private neurological practice doctors and medical care centers (N = 4) (Fig. 3) . The data source intersections of registered ALS cases to be present or absent are shown in Fig. 3 . The percentage of log-linear estimated missing ALS cases in the target population was estimated to be 18.9%. Correspondingly, a maximum total of 540 (SD = 13.1) ALS cases is estimated where source dependency is taken into account and estimation bias were minimized in optimizing logistical approaches. Compared to other statistical CARE procedures, the log-linear model included all available intersections of the data sources and took the dependency between the data sources into account. Alternative methods, which are considered less accurate, yielded results from 15.8% to 35.7% depending on the chosen estimation method and the data sources included ( table 1 ). In our study, the alternative CARE methods turned out to be conservative in source dependency in relation to sparse data and the corresponding results seemed strongly biased depending on the selection of intersections terms. Information of included interaction terms are set out in table 1 . A comparison of the total estimated ALS cases in the target population ( N ^ = 520–681) is summarized in table 1 by the missing percentages regarding the observed total ALS cases ( N = 438). Adding the estimated 18.9% CARE missing cases to the observed ALS cases, the ASR increased to 3.1 per 100,000 PY as expected for case ascertainment in the ALS registry before study beginning. Based on log-linear CARE estimated total ALS cases in the study region, the number of ALS cases, demographic characteristics and the completeness in percentage in the respective data sources are given in the following table 2 . Based on the first population based ALS registry in Germany covering a geographically defined region with about 8.4 million inhabitants, a crude incidence rate of ALS of 2.6 per 100,000 PY was estimated. The exact European ASR was 2.5 per 100,000 PY (95%-CI: 2.3 to 2.7). The male/female ratio was 1.1 and the age- distribution of the ALS cases peaked in the age group 70–74 years. The observed incidence rates and the peak were consistent with findings from other European countries, indicating that the ALS registry Swabia is well implemented. Although we found some geographical incidence variation, the differences were not statistically significant and most likely represent chance variation. The estimated completeness was 81.1% and indicates a good coverage of the registry. After correction for potentially missing cases, the ASR was estimated to a maximum of 3.1 per 100,000 PY. In our study, the crude annual incidence rate for 2009/2010 was comparable to the estimated average crude incidence rate of ALS in Europe. The ASR in Swabia was in line with the different ASRs ranging in European countries from a low of 1.5 in Lancashire and a high of 2.7 in Ireland per 100,000 PY [3,35]. A peak incidence in the age group 70–74 years is also reported by other authors [3,7,8]. A decreasing trend in the gender ratio towards one as described in recent studies [9,10] was clearly evident from our data. Our study results were also in line with ALS-incidence rates in Canada, which range from 1.6 to 2.4 for crude incidences and 2.1 to 2.3 for ASRs [36]. Higher ASRs were observed in previous studies (USA standard population) for the age group of 45 to 74 years in studies from Canada, Denmark, Finland, Italy, Ireland, Israel, Sardinia, Scotland, Sweden, USA, with a ASR range of 2.1 (Israel) to 8.5 (Middle Finland) [8]. These differences can be explained e.g. by to possible geographical variation, the underlying population size, the completeness of the registries or bias produced by weights of the standard population. Wide 95% CIs of ASRs could also partly explain the variation in the ASRs, possibly revealing different methods used in the registries to estimate epidemiological parameters. Analyzing ALS data, the geographical variation of incidences might be a result of the standard deviation or standard error occurring from the issue of sparse data. In 1996, Pringle mentioned that a compromise could be summarizing two extremes, small scaled cartographical presentation of the estimated risks (focus attention on smaller areas) and probability maps (focus attention on larger areas). Empirical Bayesian approaches offer such a possible solution by providing estimates of relative risks e.g. for each county and converting them into rates by simply ...

Similar publications

Chapter
Full-text available
This chapter looks at positive (0-truncated), zero-inflated and zero-altered (hurdle) distributions, with the focus on discrete distributions. Zero-deflated distributions are also mentioned. Specific examples include the zero-inflated Poisson and positive-binomial distributions. Another example concerns closed-population capture–recapture estimatio...

Citations

... Many registries rely only on passive (i.e., voluntary reporting of cases directly to the surveillance entity, by physicians and/or through self-report) methods to capture individuals with ALS. This is the case for ALS Registry Swabia in Germany [20,21], the Australian National Motor Neuron Disease Observational Cohort [22], the Dutch Computer Registry of All Myopathies and Polyneuropathies (CRAMP) [23], the Iran ALS Clinical Registry [24], and the Massachusetts (USA) Tracking Program [8]. Linkage (record-matching, consolidation of cases from many sources) was the main method of case ascertainment for the Norwegian Patient Registry (NPR) [25], the French Health Insurance Information System Database [26,27], the French Register of ALS in Limousin (FRALim) [28], the Integrated Neurodegenerative Disease Database (INDD) [9] in the United States, the National Administrative Healthcare Database (USA) [13,29], the Pooled Resource Open Access ALS Clinical Trials (PRO-ACT) [30] in the USA, and the All rights reserved. ...
Preprint
Background: Registries and clinical databases are important tools to systematically record and collect information about individuals with rare diseases and to monitor disease patterns in populations. Through a review of the published literature on strategies used for surveillance of Amyotrophic Lateral Sclerosis (ALS), our objective was to better delineate the varied approaches used to monitor ALS at a population level. Further, we sought to determine the potential of registries to enhance knowledge on the epidemiology of ALS using a case study comparing epidemiological outputs from registries in the United States, United Kingdom, and Italy. Summary: We searched Medline, Embase, Global Health, PsycInfo, Cochrane Library, and CINAHL identifying articles published between January 1st, 2010, and May 12th, 2021. Studies describing population registries, cohorts of individuals with ALS, or large-scale studies aimed at systematically identifying people with ALS, were eligible for inclusion. 1,447 publications were found, of which 141 were selected for full text review, and 41 of those were selected for data extraction. We identified ALS registries and pertinent databases in 4 continents (North America, Europe, Asia, and Oceania). Stated objectives of the registries/databases shaped their framework, methodology, and follow-up. The US National Registry demonstrates substantial research outputs and methodological strengths, producing many descriptive epidemiological outputs (n=5 studies) and several methodological papers (n=12 studies). The UK and Italy overall each produced a similar number of studies (albeit with fewer methodological papers), across several different registries and regions. Key Messages: Due to challenges inherent to the surveillance of rare diseases, registries are a vital tool in determining and assessing the global impact of ALS. Nevertheless, the development and implementation of registries is not feasible everywhere in the world. There are advantages and drawbacks to structuring registries at a national or regional level, often dictated by funding availability, resources and health care infrastructure, and research objectives. To fully assess the epidemiological burden of ALS globally, collaborative initiatives are needed to fill gaps in knowledge, and there is a critical need to harmonize and optimize the development, collection, and sharing of data across registries.
... The ALS registry Swabia has been described previously in detail [23][24][25] . In brief, it is a population-based clinicalepidemiological registry with the aim to collect data on all newly diagnosed ALS cases in Swabia, a defined geographic region with approximately 8.4 million inhabitants in the South-West of Germany. ...
... The standardized instruments and tests were performed identically in ALS cases and controls. Information on body mass index (BMI), smoking status, educational attainment, family history of ALS, occupation work intensity and medical history of hypertension, diabetes mellitus, chronic heart disease, and myocardial infarction was collected 24 . Response in cases was 65% (20% refused and 15% could not be contacted) and in the population-based controls 19% (39% refused and 42% did not respond after several attempts to get in contact per mail and telephone). ...
Article
Full-text available
Kidney function as part of metabolic changes could be associated with amyotrophic lateral-sclerosis (ALS). We investigated the associations between estimated chronic kidney disease (CKD), based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation, and the risk at onset and prognostic value of CKD for ALS. Between October 2010 and June 2014, 362 ALS cases (59.4% men, mean age 65.7 years) and 681 controls (59.5% men, means age 66.3 years) were included in a population-based case–control study based on the ALS registry Swabia in Southern Germany. All ALS cases were followed-up (median 89.7 months), 317 died. Serum samples were measured for cystatin C to estimate the glomerular filtration rate (eGFR) according to the CKD-EPI equation. Information on covariates were assessed by an interview-based standardized questionnaire. Conditional logistic regression models were applied to calculate odds ratios (OR) for risk of ALS associated with eGFR/CKD stages. Time-to-death associated with renal parameters at baseline was assessed in ALS cases only. ALS cases were characterized by lower body mass index, slightly lower smoking prevalence, more intense occupational work and lower education than controls. Median serum cystatin-C based eGFR concentrations were lower in ALS cases than in controls (54.0 vs. 59.5 mL/min pro 1.73 m²). The prevalence of CKD stage ≥ 3 was slightly higher in ALS cases than in controls (14.1 vs. 11.0%). In the adjusted models, CKD stage 2 (OR 1.82, 95% CI 1.32, 2.52) and stage 3 (OR 2.34, 95% CI 1.38, 3.96) were associated with increased ALS risk. In this cohort of ALS cases, eGFR and CKD stage ≥ 3 (HR 0.94; 95% CI 0.64, 1.38) were not associated with prognosis. In this case–control study, higher CKD stages were associated with increased ALS risk, while in the prospective cohort of ALS cases, no indication of an association of CysC-based CKD on mortality was seen. In addition, our work strengthens the importance to evaluate renal function using a marker independent of muscle mass in ALS patients.
... Biosamples are collected according to standard operating procedures at the time of enrollment and throughout follow-up. Capture-recapture procedures in the ALS registry Swabia showed completeness of 81.1%, indicating excellent quality for epidemiological research 29 . Control persons were acquired in the case-control substudy of the ALS registry in which, for each ALS patient enrolled between October 01, 2010, and December 31, 2014 (n=421), two sex-and age-matched control subjects were randomly selected using data from the region's registration o ce. ...
Preprint
Full-text available
Neurofilaments are biomarkers for neuroaxonal damage and are being evaluated in Amyotrophic Lateral Sclerosis (ALS) to support diagnosis, estimate prognosis, and monitor treatment effects. This study presents data on serum neurofilament levels in ALS on a population level to improve their application as individual diagnostic and prognostic biomarkers. We measured neurofilament light (NfL) and phosphorylated heavy chain (pNfH) levels in a large cohort of patients with ALS and controls from the epidemiological ALS registry Swabia. We observed that serum NfL was superior to pNfH. Using NfL Z-Scores instead of raw data and incorporating ALS-independent and ALS-specific influencing factors improved the diagnostic and prognostic ability. The high predictive value and individual longitudinal validity of serum NfL indicate its utility as an individual surrogate marker for survival and disease progression. Combiningepidemiological data and biomarker research in population-based Z-Scores might be a conceptual model of interest for other neurodegenerative diseases.
... The epidemiological ALS registry Swabia covers a target population of about 8.4 million inhabitants in the de ned geographical region Swabia in southern Germany and has been described previously [26][27][28] . ALS patients are categorized into the sub phenotypes classical ALS, primary lateral sclerosis (PLS), progressive bulbar palsy, progressive muscular atrophy (PMA), ail-arm syndrome, and ail-leg syndrome and followed up at one-year intervals, including reconciliation with the death register to ensure completeness of survival data. ...
Preprint
Full-text available
OBJECTIVE Neurofilament light (NfL) and phosphorylated heavy chains (pNfH), established as diagnostic and prognostic biomarkers in hospital-based amyotrophic lateral sclerosis (ALS) cohorts, are now surrogate markers in clinical trials. This study extends their evaluation to a population level, with the aim of advancing their full establishment and assessing the transferability of biomarker findings from controlled cohorts to real‑world ALS populations. METHODS We measured serum NfL and pNfH levels in all ALS patients (n=790) and general population controls (n=570) with available baseline samples participating in the epidemiological ALS Registry Swabia, providing platform-specific (ELLATM) reference data and Z-scores for controls, as well as reference data, disease-specific Z-scores and longitudinal data in ALS. We evaluated the diagnostic and prognostic utility of neurofilaments and quantified the impact of ALS-related factors and non-ALS confounders. RESULTS Neurofilaments showed high diagnostic and prognostic utility at the population level, with NfL superior to pNfH. The novel concept of a population-based ALS Z‑score significantly improved the prognostic utility compared to absolute raw values. Both biomarkers increased more strongly with age in controls than in ALS, and age adjustment improved diagnostic accuracy. Our data show that disease progression rates, ALS phenotype, BMI and renal function need to be considered when interpreting neurofilament levels; longitudinal neurofilament levels were generally stable in individual patients, especially when adjusted for age and baseline levels. INTERPRETATION Population-based assessment enhances the utility of particularly serum NfL as a diagnostic and prognostic biomarker in ALS and improves the translation of findings from controlled cohorts to real-world populations.
... In the north-east Tuscany, in the 2018-2021 period, the incidence of ALS corresponds to the mean value found in Europe [1], and is similar to that recently reported in Friuli-Venezia Giulia region (2.8/100,000 PY), in Southern Germany (2.5/100,000 PY), in the Netherlands (2.64/ 100,000 PY), and in Navarre, Spain, (2.47/100,000 person-years) [9][10][11][12]. The estimate of prevalence rates observed in this study is in line with the median value reported in the literature for seven European prospective prevalence studies [13]. ...
Article
Full-text available
Background: The incidence of Amyotrophic Lateral Sclerosis (ALS) varies among different geographical areas and seems to increase over time. This study aimed to examine the epidemiologic data of ALS in the north-east Tuscany and compare the results with those of similar surveys. Methods: Data from ALS cases diagnosed in Florence and Prato Hospitals were prospectively collected from 1st June 2018 to 31st May 2021. Results: The age- and sex-adjusted incidence rate of ALS in cases per 100,000 population was 2.71 (M/F ratio: 1.21), significantly higher as compared to that reported in the 1967-1976 decade in the same geographical area (0.714). The age- and sex-adjusted incidence rate among resident strangers was similar to that of the general population (2.69). A slightly higher incidence rate (4.36) was observed in the north-east area of Florence province, which includes the Mugello valley. The mean prevalence was of 7.17/100,00. The mean age at diagnosis was 69.7 years, with a peak between 70 and 79 years among men and a smoother age curve among women. Conclusions: ALS epidemiological features in north-east Tuscany are in line with other Italian and European Centers. The dramatic increase of the local disease burden over the last decades probably reflects better ascertainment methods and health system.
... Witte et al. found that in the state of Georgia four data sources combined may have collected 90.7% of cases 11 . Jordan et al. used the death certificate data to estimate that in Baltimore and Philadelphia more than 11% of ALS cases had been missed during data collection efforts in those cities 12 14 , consistent with the claim of Rosenbohm et al. that for Southern Germany the clinical-epidemiological registry had collected 80% cases 15 . ...
... Considerable effort has been made to estimate the number of unrecruited cases in ALS registries. The dominant method in literature is the capture-recapture process 1,9,11,[13][14][15][16][17][18] . The basic idea of the capture-recapture method is to build statistical models based on the overlap between different sources and use these models to estimate the total number of cases, and hence the number of unrecruited cases. ...
... Our estimation indicates that, statewide, the unrecruited cases account for less than 30% of all cases for our two-year period, which is similar to the wide range of results of the previous studies [9][10][11][12][13][14][15] . We also found that the percentage of unrecruited male cases is higher than that of female cases (34.87% vs. 21.95%), ...
Article
Full-text available
We developed a disease registry to collect all incident amyotrophic lateral sclerosis (ALS) cases diagnosed during 2016–2018 in Ohio. Due to incomplete case ascertainment and limitations of the traditional capture-recapture method, we proposed a new method to estimate the number of cases not recruited by the Registry and their spatial distribution. Specifically, we employed three statistical methods to identify reference counties with normal case-population relationships to build a Poisson regression model for estimating case counts in target counties that potentially have unrecruited cases. Then, we conducted spatial smoothing to adjust outliers locally. We validated the estimates with ALS mortality data. We estimated that 119 total cases (95% CI [109, 130]) were not recruited, including 36 females (95% CI [31, 41]) and 83 males (95% CI [74, 99]), and were distributed unevenly across the state. For target counties, including estimated unrecruited cases increased the correlation between the case count and mortality count from r = 0.8494 to 0.9585 for the total, from 0.7573 to 0.8270 for females, and from 0.6862 to 0.9292 for males. The advantage of this method in the spatial perspective makes it an alternative to capture-recapture for estimating cases missed by disease registries.
... The ALS register in the Netherlands was implemented with a similar methodology and in the years 2006-2009, collected 1217 incident cases with an estimated incidence, after the use of capture-recapture method, of 2.77 per 100 000 person-years [18]. A similar incidence was found in South Germany in Swabia, a region of eight million inhabitants, 2.5 and rising to 3.1 per 100 000 person-years after capture-recapture with about 18% of missing cases [19]. These studies show that even with registries well organized and with important resources, the missing cases, calculated with the capture-recapture method, are between 15 and 35%. ...
Article
Full-text available
Purpose of review: Amyotrophic lateral sclerosis (ALS) is a rare progressive neurodegenerative disease of motor neurons with a fatal outcome. The rareness of the disease and the rapidly fatal course are the main challenges for the ALS epidemiological research. The understanding of ALS has clearly advanced in the recent years both in the genetics and in the leading pathways of disease determinants. Epidemiological research has played a primary role in these discoveries. Recent findings: Epidemiological studies have shown a variation of incidence, mortality and prevalence of ALS between geographical areas and different populations, supporting the notion that genetic factors, linked to populations' ancestries, along with environmental and lifestyle factors, play a significant role in the occurrence of the disease. The burden of motor neuron diseases is increasing and currently more relevant in high-income countries but increasing at the highest rate in low and middle-income countries. The ALS phenotype is not restricted to motor functions. C9orf72 repeat expansion seems to present a recognizable phenotype characterized by earlier disease onset, the presence of cognitive and behavioural impairment. Summary: Population-based disease registries have played a major role in developing new knowledge on ALS, in characterizing genotype-phenotype correlations, in discovering new genetic modifiers and finally in planning research and health services, considering the high cost of motor neuron disease care. Epidemiological research based on multicentre international collaboration is essential to provide new data on ALS, especially in some regions of the world with poor data.
... EU Country Specific/Regional Registries Several local or regional registries from the EU were identified, and a sample are summarized below in Table 2. These registries are generally population-based as noted, and data collected are generally similar to that collected by the ENCALS registry (24,(26)(27)(28)(29)(30)(31)(32)(33). The identified registries generally appear to collaborate with broader registry efforts in Europe and generally use the same data collection form as the ENCALS referenced above. ...
Article
Full-text available
Understanding patient clinical progression is a key gateway to planning effective clinical trials and ultimately enabling bringing treatments to patients in need. In a rare disease like amyotrophic lateral sclerosis (ALS), studies of disease natural history critically depend on collaboration between clinical centers, regions, and countries to enable creation of platforms to allow patients, caregivers, clinicians, and researchers to come together and more fully understand the condition. Rare disease registries and collaborative platforms such as those developed in ALS collect real-world data (RWD) in standardized formats, including clinical and biological specimen data used to evaluate risk factors and natural history of disease, treatment patterns and clinical (ClinROs) and patient- reported outcomes (PROs) and validate novel endpoints. Importantly, these data support the development of new therapeutics by supporting the evaluation of feasibility and design of clinical trials and offer valuable information on real-world disease trajectory and outcomes outside of the clinical trial setting for comparative purposes. RWD may help to accelerate therapy development by identifying and validating outcome measures and disease subpopulations. RWD can also make potential contributions to the evaluation of the safety and effectiveness of new indications for approved products and to satisfy post-approval regulatory and market access requirements. There is a lack of amalgamated information on available registries, databases, and other sources of real-world data on ALS; thus, a global review of all available resources was warranted. This targeted review identifies and describes ALS registries, biobanks and collaborative research networks that are collecting and synthesizing RWD for the purposes of increasing patient awareness and advancing scientific knowledge with the hope of expediting future development of new therapies.
... Determining the quality of data is multifaceted, and previous literature suggests different parameters for data quality [3,[7][8][9]. The most repeatedly and unambiguously cited terms for data quality criteria were "accuracy", "completeness", "timeliness", "consistency", and "relevancy" [3,[10][11][12][13][14]. However, the definition of data quality criteria may be different depending on registry type. ...
Article
Descriptive study. This study aimed to develop and evaluate a systematic arrangement for improvement and monitoring of data quality of the National Spinal Cord (and Column) Injury Registry of Iran (NSCIR-IR)—a multicenter hospital-based registry. SCI community in Iran. Quality assurance and quality control were the primary objectives in improving overall quality of data that were considered in designing a paper-based and computerized case report. To prevent incorrect data entry, we implemented several validation algorithms, including 70 semantic rules, 18 syntactic rules, seven temporal rules, and 13 rules for acceptable value range. Qualified and trained staff members were also employed to review and identify any defect, inaccuracy, or inconsistency in the data to improve data quality. A set of functions were implemented in the software to cross-validate, and feedback on data was provided by reviewers and registrars. Socio-demographic data items were 100% complete, except for national ID and education level, which were 97% and 92.3% complete, respectively. Completeness of admission data and emergency medical services data were 100% except for arrival and transfer time (99.4%) and oxygen saturation (48.9%). Evaluation of data received from two centers located in Tehran proved to be 100% accurate following validation by quality reviewers. All data was also found to be 100% consistent. This approach to quality assurance and consistency validation proved to be effective. Our solutions resulted in a significant decrease in the number of missing data.
... The study is based on data from the prospective ALS-registry Swabia 4,24,25 . Approximately 8.4 million people live in the catchment area of Swabia, a defined geographic region in southwest Germany. ...
Article
Full-text available
Background A wide variety of metabolic changes, including an increased incidence of diabetes mellitus (DM) and dyslipidaemia, has been described in amyotrophic lateral sclerosis (ALS). The aim of this study was to investigate the associations of statin use and history of DM with onset of disease and survival in patients with ALS. Methods 501 patients (mean age: 65.2 ± 10.9 years; 58.5% male) from the ALS‐registry Swabia recruited between October 2010 and April 2016 were included in this prospective cohort study. Data were collected using a standardized questionnaire. Results Statin use (n=65) was not associated with overall survival (p=0.62). Age of ALS onset in patients with DM was 4.2 years (95% CI 1.3–7.2 years) later compared to patients without DM (p < 0.01). Overall survival of patients with hight body mass index at study entry (> 27.0 kg/m² = upper quartile, n=127) was prolonged by more than five months compared to patients with low BMI (< 22.0 kg/m² = lower quartile, n=123; p = 0.04). Conclusions This study supports the view that statin use is not associated with overall survival of ALS patients, suggesting that statins are not harmful and should not be discontinued in ALS. Furthermore, the delayed onset of ALS in patients with DM may mirror the potentially protective metabolic profile associated with type II DM. Consistently, this study provided further evidence that high BMI is a positive prognostic factor in ALS.